---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-006327"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:29:09.753253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed

## Summary
- Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.
- Common stock to trade under symbol KYNB on Nasdaq at market open Jan 8, 2026; CUSIP unchanged.
- CEO cites sale of FibroGen China, payoff of term loan, and cash runway extended into 2028.
- FG-3246 Phase 2 monotherapy interim results expected H2 2026; topline Phase 1b/2 combo at ASCO GU Q1 2026.
- Roxadustat granted FDA Orphan Drug Designation for MDS; pivotal Phase 3 protocol submitted.

## SEC filing metadata
- accession: 0001193125-26-006327
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/fgen-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-006327
- JSON: https://secwatch.observer/filing/0001193125-26-006327.json
- Plain text: https://secwatch.observer/filing/0001193125-26-006327.txt

## Source-grounded claims
- claim_id: 0cdf713694d65e36548c2b695c3ced91598752fd
  claim: KYNTRA BIO, INC.: Amended certificate of incorporation to change company name from FibroGen, Inc. to Kyntra Bio, Inc (effective 2026-01-07).
  evidence_excerpt: On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm
- claim_id: 2e432c168d52cef62c8cde2aa70caa84647445a0
  claim: KYNTRA BIO, INC.: Amended bylaws solely to update the title to reflect the company's new name, Kyntra Bio, Inc (effective 2026-01-07).
  evidence_excerpt: The Board also approved the amendment of the Company’s Bylaws, effective at 4:30 p.m. Eastern Time on January 7, 2026, solely to update the title of the Bylaws to reflect the Company’s new name, Kyntra Bio, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.